Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Mohammed Milhem
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07404332CT.gov 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | — | Recruiting | — | — | — |
NCT07094113CT.gov AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT07046923CT.gov A Study of LY4175408 in Participants With Advanced Cancer | — | Recruiting | — | — | — |
NCT06395090CT.gov A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) | — | Withdrawn | — | — | — |
NCT06460961CT.gov A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) | — | Active Not Recruiting | — | — | — |
NCT06119581CT.gov A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05614739CT.gov FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | — | Recruiting | — | — | — |
NCT04521621CT.gov A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | — | Terminated | — | — | — |
NCT04294576CT.gov Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors | — | Unknown | — | — | — |
NCT04135352CT.gov A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) | — | Terminated | — | — | — |
Show 4 more trialsShow fewer
NCT03383094CT.gov Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT03257722CT.gov Pembrolizumab + Idelalisib for Lung Cancer Study | — | Terminated | — | — | — |
NCT02414269CT.gov Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | — | Active Not Recruiting | — | — | — |
NCT02376699CT.gov Safety Study of SEA-CD40 in Cancer Patients | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Mohammed Milhem | P3 | B · 62 |
| Oxaliplatin | Ruijin Hospital | P4 | BBB |
| Fluorouracilum | Ruijin Hospital | P4 | BBB |
| Irinotecan | Eli Lilly and Company | P4 | BBB |
| Dexasone | Janssen Research & Development, LLC | P2 | BBB |
| Atezolizumab | UNC Lineberger Comprehensive Cancer Center | P2/3 | BB |
| Ipilimumab | 7 Hills Pharma, LLC | P3 | BB |
| Trastuzumab | City of Hope Medical Center | P3 | BB |
| Margetuximab | MacroGenics | P3 | BB |
+41 more in the Metastatic Neoplasm cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Metastatic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-metastatic-neoplasm-34416
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →